Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: The Kaiser Permanente Southern California cohort

Journal of Hypertension

Volumn 29, Issue 11, 2011, Pages 2226-2235

  Sim, John J ^a   Shi, Jiaxiao ^b   Calara, Federico ^c   Rasgon, Scott ^a   Jacobsen, Steven ^b   Kalantar Zadeh, Kamyar ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

chronic kidney disease; epidemiology; plasma renin activity; risk factors

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE; HISPANIC; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEGRO; PLASMA RENIN ACTIVITY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

EID: 80054113400     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834bbc8a     Document Type: Article

References (34)

1. Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, et al. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55:867-877.
2. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993; 329:616-619. (Pubitemid 23244813)
3. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007; 28:2644-2652. (Pubitemid 350071528)
4. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10:1-8. (Pubitemid 27038966)
5. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877-885.
6. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
7. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, et al. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010; 106:764-769.
8. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17:1-7. (Pubitemid 38064751)
9. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010; 16:964-970.
10. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25:292-299. (Pubitemid 38295437)
11. Vergaro G, Emdin M. Cardiac angiotensin receptor expression in hypothyroidism: back to fetal gene programme? J Physiol 2008; 586:7-8.
12. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011. [Epub ahead of print]
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
14. Bhandari SK, Pashayan S, Liu IL, Rasgon SA, Kujubu DA, Tom TY, et al. 25-hydroxyvitamin d levels and hypertension rates. J Clin Hypertens (Greenwich) 2011; 13:170-177.
15. Katz FH, Romfh P, Smith JA. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40:125-134.
16. Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966; 45:1587-1592.
17. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37:1811-1819. (Pubitemid 121000617)
18. Brunner HR, Baer L, Sealey JE, Ledingham JG, Laragh JH. The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest 1970; 49:2128-2138.
19. Laragh JH. The role of aldosterone in man. Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. JAMA 1960; 174:293-295.
20. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
23. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
24. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431. (Pubitemid 35340538)
25. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:936-946. (Pubitemid 40563242)
26. Meade T. Review: plasma renin and the incidence of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11:91-98.
27. Gutkin M, Levinson GE, King AS, Lasker N. Plasma renin activity in endstage kidney disease. Circulation 1969; 40:563-574.
28. Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG. Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 1971; 285:757-762.
29. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1091-1096. (Pubitemid 20370729)
30. Tu WH. Plasma renin activity in acute tubular necrosis and other renal diseases associated with hypertension. Circulation 1965; 31:686-695.
31. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342:1350-1358. (Pubitemid 30408720)
32. Suthanthiran M, Gerber LM, Schwartz JE, Sharma VK, Medeiros M, Marion R, et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009; 76:72-80.
33. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902. (Pubitemid 35434913)
34. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14 (6 Pt 1):491-503. (Pubitemid 32506721)